On 14 May, the Biotechnology Innovation Organisation (BIO) - the largest trade organisation in the world that represents the biotechnology industry - released a new report, “The State of Innovation in Highly Prevalent Chronic Diseases Volume IV: Alzheimer’s Disease Therapeutics”. This report is the fourth in a series on the innovation landscape of highly prevalent, chronic diseases. This volume takes an in-depth look at the state of innovation for therapeutics in Alzheimer’s disease (AD). The analysis, which aims to assess the depth and breadth of innovation to meet the needs of people with AD, also features historical clinical success rates, failed mechanistic strategies, as well as trends in venture financing and investment into new clinical trials.
Download it here: http://go.bio.org/rs/490-EHZ-999/images/BIO_HPCD4_ALZHEIMERS.pdf
